Testing a new spinal injection treatment for ALS

Plain-English translation of NCT07290062 on ClinicalTrials.gov ↗ · Source last updated September 2026 · Translation generated July 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This early-stage trial is testing INS1202, a new treatment delivered directly into the fluid surrounding your spinal cord with a single injection. The study aims to find the safest dose and learn how the medication works in people with ALS, including those with specific genetic forms of the disease. Researchers will carefully monitor your health and symptoms after the injection to understand whether this treatment is safe and how it affects your body.

ALS is a serious disease that progressively weakens muscles and currently has very few effective treatments. This study exists because researchers believe delivering treatment directly to the spinal cord—where ALS causes damage—may be a more effective way to help people with this condition.

Do you qualify?

You likely qualify if…

you are diagnosed with amyotrophic lateral sclerosis (ALS) using standard diagnostic criteria
you are between 18 and 79 years old
you have had ALS symptoms for 42 months or less
you have a healthy enough body weight and general health status to participate
you either have sporadic ALS (no family history) or a confirmed SOD1 genetic mutation, depending on which group you join

You likely don't qualify if…

you have previously received cellular therapy or gene therapy for ALS
you are currently taking experimental medications or treatments for ALS or any other condition
you have other genetic mutations associated with familial ALS (other than the specific ones being studied)

What participation looks like

You will visit the research center on Day 1 to receive a single spinal injection of the medication—a procedure similar to a lumbar puncture. The study team will perform safety checks, blood tests, and neurological examinations before and after the injection to monitor how you respond. You will have follow-up visits and assessments over the following weeks and months so the researchers can track your safety and how the medication may be affecting your ALS symptoms.

AI-generated summary from trial data · Jul 10, 2026 · Not medical advice

Trial locations(7 sites)

United States

USA004, La Jolla, California

USA002, Palo Alto, California

USA003, Baltimore, Maryland

USA009, Worcester, Massachusetts

USA001, Columbia, Missouri